Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK139 injection in seasonal allergic rhinitis (phase II, randomized, double-blind, placebo-controlled)
CTR20260593Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK139 in seasonal allergic rhinitis (SAR), sponsored by Akeso, Inc.. Started Feb 2026; status: active.
02
Drugs
AK139
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20260593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260593.